On February 20, 2026, the U.S. Food and Drug Administration sent warning letters to 30 telehealth companies over misleading website claims about compounded GLP-1 drugs. For anyone researching how to get GLP-1 medication, the action changed the question itself. It is no longer only about convenience; it is about safety and legitimacy.
This article explains what a rigorous, physician-supervised GLP-1 evaluation actually involves, so readers can measure any provider, telehealth or in-person, against that standard. It covers the regulatory context, the clinical pathway legitimate prescribers follow, and the steps fast-turnaround models commonly skip.
What the 2026 FDA Crackdown Signals
The February action targeted claims about compounded semaglutide and tirzepatide products marketed by telehealth companies. It was the second wave of enforcement since the agency’s September 2025 crackdown on misleading direct-to-consumer pharmaceutical advertising, a campaign that has since produced thousands of warning letters.
The FDA’s core message was direct: telehealth marketing of compounded drugs must not mislead consumers about what those products are or how they are regulated. Readers who want to verify the details can consult the FDA’s own press announcement on the warning letters and the legal analysis published by Foley & Lardner on the agency’s 2026 enforcement priorities.
Why Every GLP-1 Medication Requires a Licensed Clinician’s Evaluation
Every FDA-approved GLP-1 medication is prescription-only in the United States. There is no legitimate route to one without a licensed clinician evaluating the patient first. Options a clinician may discuss include brand-name GLP-1s like Zepbound and compounded GLP-1 medications, which may be incorporated within a broader, physician-supervised program such as Red Mountain’s RM3®.
The prescription requirement is not red tape. It exists because of the medication’s risk profile, which becomes clear in the contraindication review below.
What a Legitimate GLP-1 Prescribing Pathway Looks Like
The following four components form a baseline clinical checklist that any provider should meet, regardless of delivery model. They are a minimum standard, not an exhaustive list.
BMI and Comorbidity Screening
Most adults qualify for GLP-1 therapy with a BMI of 30 or higher, or a BMI of 27 or higher plus at least one weight-related condition, such as high blood pressure, high cholesterol, or sleep apnea. Most employer insurance plans now require documentation of these criteria for prior authorization, which underscores that this is a clinical standard rather than an arbitrary hurdle.
Baseline Metabolic Labs
Baseline labs typically include:
- Comprehensive metabolic panel (CMP)
- HbA1c
- Lipid panel
- Thyroid function (TSH), when clinically relevant
The American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) both recommend baseline metabolic labs before initiating GLP-1 therapy. Even so, some major telehealth brands do not require labs at intake. That gap is worth understanding before choosing a provider.
Contraindication Review
Every FDA-approved GLP-1 receptor agonist carries a boxed warning, the most serious safety warning the FDA can place on a label short of market removal, based on thyroid C-cell tumor findings in rodent studies.
The labels list two absolute contraindications:
- A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2)
- A known serious hypersensitivity reaction to the drug
Labels also warn that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been observed, and instruct clinicians to discontinue promptly if pancreatitis is suspected.
Each of these depends on a thorough personal and family history. A 5- to 10-minute questionnaire may not surface that history with the same rigor as a clinician-led conversation that can ask follow-up questions.
Physical Exam
An in-person exam can identify what self-reported symptoms often cannot: gallbladder tenderness, relevant thyroid findings, and dehydration risk, which can contribute to acute kidney injury when gastrointestinal side effects occur.
A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society recommends a comprehensive physical exam before GLP-1 initiation, including muscle strength and function testing. The same advisory calls for baseline nutritional assessment, screening for eating and mood disorders, evaluation of social determinants of health, and a full lifestyle assessment. These elements are difficult to deliver in a telehealth-only encounter.
What an Async Quiz-to-Doorstep Model Typically Skips
Many telehealth platforms use an asynchronous model: an online questionnaire of roughly 5 to 10 minutes, reviewed by a licensed clinician, with no in-person visit and often no labs.
The core limitation is structural. Without a physical exam, findings such as thyroid palpation or injection site assessment are limited to what the patient self-reports. This is the marketing pattern the FDA’s 2026 warning letters targeted: compounded GLP-1 claims made without the clinical rigor the medication’s risk profile requires.
Why Ongoing Monitoring Matters as Much as the Initial Visit
GLP-1 therapy is not a one-time prescribing event. Regular in-person checks can track the modest heart rate increases associated with GLP-1 therapy, while ongoing labs help assess effectiveness and safety over time, including:
- Weight response
- Renal and hepatic function
- Lipid levels
- A1c
The World Health Organization’s December 2025 guideline reinforces this approach. It conditionally recommends GLP-1 therapies as a long-term treatment for adults with obesity, integrated with intensive behavioral therapy within a comprehensive, multimodal care model rather than as a standalone prescription.
Understanding Cost and Coverage Before Starting Treatment
Cost is a real barrier. Obesity medications carry list prices of roughly $1,000 to $1,350 per month before insurance.
Coverage is shifting. Nearly half of large employers covered GLP-1 medications in 2025, but more cut back in 2026, with further cuts under discussion for 2027. Plans that still cover them typically use strict utilization management, with prior authorization requiring documentation of BMI 30+ or BMI 27+ with a qualifying condition.
For Medicare beneficiaries, the GLP-1 Bridge program runs from July 1, 2026 through December 31, 2027. Eligible beneficiaries pay a flat $50 monthly copay on covered GLP-1 medications, with CMS covering the remaining balance of the roughly $245 monthly cost.
Cash-pay practices such as Red Mountain do not accept insurance, though Health Savings Account funds may apply when weight loss is tied to a doctor-diagnosed medical condition. Patients should confirm eligibility with their HSA administrator.
A Framework for Evaluating Any GLP-1 Provider
Readers can use these questions to vet any option:
- Does the intake include a physical exam?
- Are baseline labs ordered before prescribing?
- Is BMI and comorbidity documentation reviewed by a licensed clinician?
- Is there a clear plan for contraindication screening and ongoing monitoring?
It is also reasonable to ask directly how a provider handles thyroid and pancreatitis history, and what happens if side effects or lab abnormalities appear after the first prescription. This checklist is the practical takeaway from the FDA’s enforcement action: a way to separate marketing claims from clinical substance.
What Rigorous, Physician-Supervised Care Looks Like in Practice
Red Mountain illustrates the standard described above. It operates brick-and-mortar clinics with in-person providers rather than an app-only or async-only model, and it draws on more than 30 years of real-world patient outcomes and clinical data.
Within Red Mountain’s approach, GLP-1 medication, whether a brand-name option or a compounded GLP-1 medication, is treated as one tool within a longer-term metabolic correction plan. That plan is supported by labs, physical evaluation, and ongoing monitoring designed to help minimize side effects, preserve muscle mass, and maintain nutrient balance. The structure and clinical guidance surrounding the medication, not the medication alone, carry the work forward.
Conclusion: Treat the Evaluation, Not the Speed, as the Deciding Factor
The 2026 FDA enforcement action signals that how a GLP-1 is prescribed matters as much as whether it is prescribed at all. A legitimate pathway includes BMI and comorbidity screening, baseline labs, contraindication review, a physical exam, and ongoing monitoring.
Convenience and safety are not mutually exclusive. However, a provider that skips labs or physical exams to move faster is cutting corners on the very steps designed to protect patients. Choosing a provider is a long-term clinical decision, not a one-time transaction.
Next Step: Asking the Right Questions Before Starting
The evaluation framework above is useful in any conversation with any provider. It is also the kind of evaluation Red Mountain walks patients through in consults, grounded in decades of in-person clinical oversight. For readers who find this process unfamiliar, or missing from the options they have seen so far, a consult is usually the next step toward clear answers.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.